Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 19 of 47

18 Clinical OMICs January/February 2017 Diagnostics Biodesix Lines Up VeriStrat Collaboration in China Cancer diagnostics company Biodesix, makers of the VeriStrat test, announced a collaboration with Beijing, China-based Bioyong Technology. Under the terms of the deal, Bioyong will develop and commercialize a version of the VeriStrat proteomic blood test for patient with non-small cell lung cancer for use in China, with potential future expansion to other countries in the region. The move marks the first commer- cial entry for Biodesix in the Chinese market, though the company has main- tained relationships with researchers in the region. This is a tremendous opportunity for the company, and for lung cancer patients in Greater China," Biodesix CEO David Brunel told Clinical OMICs. "Lung cancer is a major problem in China. There are nearly 850,000 new lung cancer diagnoses predicted in 2020 and approximately 37% of new cases of lung cancer, worldwide, are in China." According to Brunel, the opportunity for the company extends well beyond simply developing and marketing a targeted cancer test. It's partner, Bioyong, is also keen to develop new tests on the VeriStrat platform that can be used in clini- cal studies with major hospitals in the region—activity that should build interest for the product. The collaboration, however, will require significant work for technology trans- fer, specifically for Biodesix's proprietary MALDI methods. Bioyong will pay Bio- desix roughly $38 million over the course of the 10-year agreement, and will be responsible for development, clinical validation, regulatory approval, and com- mercialization of a version of the VeriStrat test in their territory. In addition, the two companies will work together to advance promote the use of MALDI for clinical applications. "Building on our leadership in the clinical application of mass spectrometry, Bioyong looks forward to helping physicians make more informed treatment decisions, and provide better recovery and prognostic possibilities for patients suffering from lung cancer," notes founder and chairman Dr. Qingwei Ma. The combination of Biodesix and Bioyong is one of like minds, Brunel adds. "Both companies are trying to advance the use of MALDI-TOF in the clinic. Bioy- ong works in peptidomics and design/build of MALDI-TOF machines. Partner- ing with them means that we can focus on mutual clinical requirements, and they can expand their machine footprint and maybe design machines that reflect our mutual needs for MALDI-TOF."—Chris Anderson Molecular Stethoscope Secures $8.2M Seed Financing, Pfizer Research Deal Liquid biopsy test developer Molecular Stethoscope said that it has completed an $8.2 million seed financing. Investors include DCVC (Data Collective), Pfizer, Index Ventures, and others. The funding will enable Molecular Stethoscope to continue development of its proprietary first-in-class liquid biopsy tests. for its initial applications in cardiometabolic, and neurodegenerative diseases, and to accelerate discovery in additional markets. The company also signed a two-year research collaboration agreement with Pfizer to develop a blood-based assay that can help identify those subjects at critical stages of disease progression in key cardiometabolic conditions. "We have made significant progress over the past year and have demon- strated proof-of-concept in several important diagnostic areas," said Tina S. Nova, Ph.D., president and CEO. "We look forward to working with Pfizer to further demonstrate the value of our technology in helping to aid research, particularly in areas of high unmet medical need." Molecular Stethoscope was co - founded by Stephen Quake, Ph.D., who has founded a number of successful life science firms including Fluidigm and Helicos Biosciences, and Eric Topol, M.D., of the Scripps Translational Science Institute. Biodesix quickshooting / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017